
News|Articles|August 1, 2009
FDA Pipeline preview, August 2009 (trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, velaglucerase alfa)
Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and velaglucerase alfa
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transparency paves the way for lower costs and equitable access
2
New self-injectable biologics promise cost savings and patient convenience
3
Evaluating Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease: Written Recap
4
Stanford scientists find link between Epstein-Barr virus and lupus
5






















































